Polymer nanoparticle for oral anticancer drug delivery
The U.S. Food and Drug Administration has issued three guidances designed to help ensure the safety of FDA-regulated products in the supply chain. The documents issued today include the following: Final Guidance for Industry on Voluntary Third-Party Certification Programs for Foods and Feeds; Draft Guidance for Industry on Submission of Laboratory Packages by Accredited Laboratories;
Full Post: New FDA guidelines for foods and feeds
One of the problems that cancer patients face is that many of the most potent anticancer therapies can be administered only by injection, which means that cancer patients must travel to receive their medication. But thanks to a new type of nanoparticle developed by researchers at the Johns Hopkins University School of Medicine, future cancer patients may be able to receive their medication in pill form.
Anirban Maitra, M.D., and colleagues developed the new polymeric nanoparticle from three different starting materials that they then linked together in various proportions. The investigators found that nanoparticles made of six parts N-isopropylacrylamide, two parts methylmethacrylate, and two parts acrylic acid had suitable pharmacological properties. Indeed, nanoparticles of this composition readily incorporated water-insoluble drugs and were capable of delivering those drugs into the bloodstream after oral administration.
In a paper published in the journal Molecular Cancer Therapeutics, the researchers noted that they chose the three starting materials because they expected that the resulting polymers would stick to the mucosal layer in the gastrointestinal tract. This adhesive property gives cells in the gastrointestinal tract cells the opportunity to engulf the nanoparticles and ferry them into the bloodstream.
Tests with the anticancer drug rapamycin showed that this formulation had good pharmacokinetic properties in test animals. More importantly, these nanoparticles were able to deliver rapamycin to human pancreatic tumors implanted in the test animals. In fact, assays showed that oral dosing with this nanoparticle formulation triggered the changes in tumor cell biochemistry expected from rapamycin administration. Additional tests showed that even “mega” doses of empty nanoparticles administered for 4 weeks caused no apparent toxicities.
This work, which was supported in part by the National Cancer Institute, is detailed in the paper “In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities.” Investigators from the University of Delhi and the University Medical Center Utrecht also participated in this study. An abstract of this paper is available from the journal’s Web site. View abstract
One of the hallmarks of many nanoparticle-based anticancer therapeutics and imaging agents is that they accumulate in tumors thanks to the fact that they are small enough to escape from the bloodstream through the leaky blood vessels that surround tumors. And although many if not most tumors are surrounded by leaky blood vessels, the
Full Post: Nanoparticle reports on drug delivery to breast tumors, predicts response to therapy
One of the key steps in the development of any drug or imaging agent intended for human use is measurement of the adsorption, metabolism, and excretion of the drug. Quantifying this collection of pharmacological properties, known as ADME, is a challenging and time-consuming process that is even more difficult when the drug or imaging
Full Post: Measuring nanoparticle behavior in the body using MRI
Working with a nanoparticle designed to target and image glioblastoma, a form of brain cancer, investigators at the University of Washington in Seattle have found that these same nanoparticles inhibit tumor cell invasion, one of the key events that leads to the metastatic spread of cancer. The investigators have also determined how the nanoparticles exert
Full Post: Toxin-nanoparticle combo inhibits brain cancer invasion while imaging tumors
A research team from the Massachusetts Institute of Technology (MIT)-Harvard Center for Nanotechnology Excellence has custom-designed nanoparticles that can deliver the anticancer drug cisplatin specifically to prostate cancer cells. The nanoparticles are composed of two different polymers and are decorated with a nucleic acid aptamer that binds to the tumor marker prostate-specific membrane antigen.
Full Post: Targeted nanoparticles boost platinum-based anticancer therapy
Antibodies that target epidermal growth factor receptor (EGFR) have proven themselves as potent anticancer drugs. Now, a team of investigators led by Shuming Nie, Ph.D., and Lily Yang, Ph.D., both at the Emory University School of Medicine and members of the Emory-Georgia Tech Nanotechnology Center for Personalized and Predictive Oncology, is aiming to capitalize on
Full Post: Artificial antibody delivers nanoparticles to tumors